万赛维的注意事项

It is a special antiviral drug mainly used to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) and also used to prevent CMV infection in high-risk solid organ transplant patients. But it is a medicine with three parts poison. What should you pay attention to when taking Vancevit?

1. The absolute bioavailability of Vansevir tablets measured by ganciclovir is 10 times higher than that of ganciclovir capsules. Valganciclovir hydrochloride tablets cannot replace ganciclovir capsules in a 1:1 ratio. Patients who previously used ganciclovir capsules and want to switch to valganciclovir hydrochloride tablets should be informed that there is a risk of overdose if they take more than the prescribed dose of valganciclovir hydrochloride tablets.

2. It is recommended to monitor complete blood count and platelet count during treatment. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor therapy and/or consider suspending medication.

3. For patients with renal insufficiency, the dose needs to be adjusted according to the creatinine clearance rate.

4. For patients who have undergone hemodialysis (CrCl<10 mL/min), no recommended dose can be given. Therefore, Valganciclovir Hydrochloride Tablets cannot be used in such patients.

5. Convulsions, sedation, dizziness, ataxia and/or mental confusion have been reported after the use of valganciclovir hydrochloride tablets and/or cyclovir. If these conditions occur, they may affect activities that require concentration, including the patient's ability to drive a car and operate machinery.

6. Convulsions have been reported in patients taking imipenem-cilastatin (Taineng) and ganciclovir together. Valganciclovir hydrochloride tablets should not be used concomitantly with Tylenol unless the possible benefits outweigh the potential risks.

7. Both Zidovudine and Vancevir may cause neutropenia and anemia when used alone. Some patients may not tolerate the full dose of these two drugs.

8. The plasma concentration of didanosine may increase when used in combination with Vancevir; therefore, patients should be closely monitored for didanosine toxicity.

9. Concomitant use of Valganciclovir Hydrochloride Tablets with other drugs known to have bone marrow suppression or are related to renal insufficiency may lead to increased toxicity.

10. No safety and efficacy studies have been conducted in children. Because the pharmacokinetics of valganciclovir hydrochloride tablets have not been studied in children, use in children is not recommended.